ArticleDiabetes technology & therapeutics2015
The Michigan Model for Coronary Heart Disease in Type 2 Diabetes: Development and Validation.
Article in Diabetes technology & therapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- A Systematic Review of Methodologies Used in Models of the Treatment of Diabetes Mellitus.PharmacoEconomics · 2024Pooled it
- A systematic review of whole disease models for informing healthcare resource allocation decisions.PloS one · 2023Pooled it
- Trial
- Cost-effectiveness of Telephone-Delivered Education and Behavioral Skills Intervention for African American Adults with Diabetes.Ethnicity & disease · 2021Trial
- A Microsimulation Model for Chronic Kidney Disease Progression in Type 2 Diabetes Patients in the United States: Michigan Model for Diabetes-Chronic Kidney Disease Model.Medical decision making : an international journal of the Society for Medical Decision Making · 2026Article
- Cost-Effectiveness of Prehospital Delay Reduction Versus Primary Stroke Prevention in US Adults With Type 2 Diabetes.Stroke · 2026Article
- Cost-Effectiveness of Primary Prevention of Stroke in Type 2 Diabetes in the United States: A Microsimulation Analysis.Journal of general internal medicine · 2026Article
- Dapagliflozin and sacubitril on myocardial microperfusion in patients with post-acute myocardial infarction heart failure and type 2 diabetes.World journal of clinical cases · 2024Article
- A New Type 2 Diabetes Microsimulation Model to Estimate Long-Term Health Outcomes, Costs, and Cost-Effectiveness.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2023Article
- Cost-effectiveness of carotid artery stenting vs endarterectomy: A simulation.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2023Article
- Targeting of the diabetes prevention program leads to substantial benefits when capacity is constrained.Acta diabetologica · 2021Article
- Article
- Economic Simulation Modeling in Type 2 Diabetes.Current diabetes reports · 2020Review
- TECH-VER: A Verification Checklist to Reduce Errors in Models and Improve Their Credibility.PharmacoEconomics · 2019Article
- Development and Validation of PREDICT-DM: A New Microsimulation Model to Project and Evaluate Complications and Treatments of Type 2 Diabetes Mellitus.Diabetes technology & therapeutics · 2019Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 2 institutions in 3 countries.
Funding
Abstract
objectivesThe aim of this study was to develop and validate a computer simulation model for coronary heart disease (CHD) in type 2 diabetes mellitus (T2DM) that reflects current medical and surgical treatments. RESEARCH DESIGN AND
methodsWe modified the structure of the CHD submodel in the Michigan Model for Diabetes to allow for revascularization procedures before and after first myocardial infarction, for repeat myocardial infarctions and repeat revascularization procedures, and for congestive heart failure. Transition probabilities that reflect the direct effects of medical and surgical therapies on outcomes were derived from the literature and calibrated to recently published population-based epidemiologic studies and randomized controlled clinical trials. Monte Carlo techniques were used to implement a discrete-state and discrete-time multistate microsimulation model. Performance of the model was assessed using internal and external validation. Simple regression analysis (simulated outcome=b(0)+b(1)×published outcome) was used to evaluate the validation results.
resultsFor the 21 outcomes in the six studies used for internal validation, R(2) was 0.99, and the slope of the regression line was 0.98. For the 16 outcomes in the five studies used for external validation, R(2) was 0.81, and the slope was 0.84.
conclusionsOur new computer simulation model predicted the progression of CHD in patients with T2DM and will be incorporated into the Michigan Model for Diabetes to assess the cost-effectiveness of alternative strategies to prevent and treat T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.